SB 220025 trihydrochloride
SIGMA/S9070 - ≥98% (HPLC), solid
Synonym: 5-
CAS Number: 197446-75-6
Empirical Formula (Hill Notation): C18H19FN6 · 3HCl
Molecular Weight: 447.76
MDL Number: MFCD08705333
Linear Formula: C18H19FN6 · 3HCl
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white |
| form | solid |
| InChI | 1S/C18H19FN6.3ClH/c19-13- |
| InChI key | IPFBHUGKKONHFR-UHFFFAOYSA |
| originator | GlaxoSmithKline |
| Quality Level | 100 ![]() |
| SMILES string | Cl[H].Cl[H].Cl[H].Nc1nccc |
| solubility | H2O: 22 mg/mL |
| Application: | SB 220025 trihydrochloride may be used in p38-mediated cell signaling studies. |
| Biochem/physiol Actions: | SB 220025 is a potent, specific inhibitor of human p38 MAP kinase (IC50 = 60 nM). |
| Biochem/physiol Actions: | SB 220025 is a potent, specific inhibitor of human p38 mitogen-activated protein (MAP) kinase, with an IC50 value of 60 nM and 50- to 1000-fold selectivity. SB 220025 reduces inflammatory cytokine production and inhibits angiogenesis. SB 220025 reduced the lipopolysaccharide-induce |
| Features and Benefits: | This compound is featured on the MAPKs page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here . |
| Features and Benefits: | This compound was developed by GlaxoSmithKline . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 2 mg in glass bottle |
| Packaging: | 500 μg in glass bottle |
| Symbol | GHS06 |
| Signal word | Danger |
| Hazard statements | H301 - H315 - H319 - H335 |
| Precautionary statements | P301 + P310 + P330 - P302 + P352 - P305 + P351 + P338 |
| Hazard Codes | T |
| Risk Statements | 25-36/37/38 |
| Safety Statements | 26-36-45 |
| RIDADR | UN 2811 6.1 / PGIII |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| UNSPSC | 12352200 |


